Skip Navigation


Journal of Tropical Pediatrics Advance Access originally published online on February 8, 2009
Journal of Tropical Pediatrics 2009 55(5):341-342; doi:10.1093/tropej/fmp003
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
55/5/341    most recent
fmp003v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Weckx, L. Y.
Right arrow Articles by Moraes-Pinto, M. I. d.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weckx, L. Y.
Right arrow Articles by Moraes-Pinto, M. I. d.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2009]. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Optimization Strategy to Minimize Wastage of Palivizumab during the 2008 RSV Season in Sao Paulo, Brazil

Lily Yin Weckx, Márcia Monteiro Alves Fernandes, Ana Isabel Melo Pereira Monteiro, Alessandra Ramos Souza and Maria Isabel de Moraes-Pinto

Division of Pediatric Infectious Diseases, Federal University of São Paulo, São Paulo, Brazil

Correspondence: Maria Isabel de Moraes-Pinto, Division of Pediatric Infectious Diseases, Federal University of São Paulo, Rua Pedro de Toledo, 781, 9 andar, 04039-032 São Paulo, SP, Brazil. Tel.: +55 11 5574 6471; Fax: +55 11 5575 6928. E-mail: <m.isabelmp{at}uol.com.br>.


  Abstract

Palivizumab is currently recommended to high-risk children as a prophylaxis for respiratory syncytial virus (RSV) infection. However, it is still very expensive for developing countries like Brazil. Herein, we describe our strategy to minimize wastage of Palivizumab during the 2008 RSV season. Appointments were fixed for 304 children on 2 days of the week, so that a mean of 19.9 children received Palivizumab per day. That allowed remaining volumes of Palivizumab vials to be pooled and used for other children on the same day within the 6 h period after opening a vial. That strategy saved 26.3% of vials, which represents USD749 143.75.

Key Words: Palivizumab • prophylaxis • respiratory syncytial virus


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.